F Wild1. 1. Wissenschaftliches Institut der PKV (WIP), Gustav-Heinemann-Ufer 74c, 50968, Köln, Deutschland. frank.wild@wip-pkv.de
Abstract
BACKGROUND: For persons covered by statutory health insurance (SHI) an increase in the number of defined daily doses (DDD) for pharmaceuticals to treat multiple sclerosis (MS) is known but so far there has been no comparable survey for private health insurance (PHI). Moreover, there are gaps in knowledge of the reasons for the increase and concerning the number of the MS patients in Germany. MATERIAL AND METHODS: The study is based on pharmaceutical data of the PHI in Germany. The projection takes into account the different prevalence and the different male/female relationship in SHI and PHI in an extrapolation to the total population. RESULTS: From 2006 to 2010 the number of DDDs of MS pharmaceuticals increased by approximately 91.6 % (SHI 39.9 %) per insured person. The increase in the PHI is mainly based for on an increase in the number of MS patients. The total number of MS patients in Germany was estimated to be approximately 146,000 whereby some 12,700 MS patients (8.7 %) were insured in PHI. CONCLUSION: There is a need for research into the reasons for the increase in MS patients. The disproportional increase in the PHI compared to SHI could be a result of the increase of insured persons and an increased inclusion of persons with a higher risk of the disease.
BACKGROUND: For persons covered by statutory health insurance (SHI) an increase in the number of defined daily doses (DDD) for pharmaceuticals to treat multiple sclerosis (MS) is known but so far there has been no comparable survey for private health insurance (PHI). Moreover, there are gaps in knowledge of the reasons for the increase and concerning the number of the MSpatients in Germany. MATERIAL AND METHODS: The study is based on pharmaceutical data of the PHI in Germany. The projection takes into account the different prevalence and the different male/female relationship in SHI and PHI in an extrapolation to the total population. RESULTS: From 2006 to 2010 the number of DDDs of MS pharmaceuticals increased by approximately 91.6 % (SHI 39.9 %) per insured person. The increase in the PHI is mainly based for on an increase in the number of MSpatients. The total number of MSpatients in Germany was estimated to be approximately 146,000 whereby some 12,700 MSpatients (8.7 %) were insured in PHI. CONCLUSION: There is a need for research into the reasons for the increase in MSpatients. The disproportional increase in the PHI compared to SHI could be a result of the increase of insured persons and an increased inclusion of persons with a higher risk of the disease.
Authors: P Flachenecker; U K Zettl; U Götze; J Haas; S Schimrigk; W Elias; M Pette; M Eulitz; M Hennig; J Bertram; R Hollweck; A Neiss; M Daumer; D Pitschnau-Michel; P Rieckmann Journal: Nervenarzt Date: 2005-08 Impact factor: 1.214
Authors: Kristin Stuke; Peter Flachenecker; Uwe K Zettl; Wolfgang G Elias; Matthias Freidel; Judith Haas; Dorothea Pitschnau-Michel; Sebastian Schimrigk; Peter Rieckmann Journal: J Neurol Date: 2009-07-23 Impact factor: 4.849
Authors: Peter Flachenecker; Kristin Stuke; Wolfgang Elias; Matthias Freidel; Judith Haas; Dorothea Pitschnau-Michel; Sebastian Schimrigk; Uwe K Zettl; Peter Rieckmann Journal: Dtsch Arztebl Int Date: 2008-02-15 Impact factor: 5.594
Authors: Ashutosh Malhotra; Michaela Gündel; Abdul Mateen Rajput; Heinz-Theodor Mevissen; Albert Saiz; Xavier Pastor; Raimundo Lozano-Rubi; Elena H Martinez-Lapiscina; Elena H Martinez-Lapsicina; Irati Zubizarreta; Bernd Mueller; Ekaterina Kotelnikova; Luca Toldo; Martin Hofmann-Apitius; Pablo Villoslada Journal: PLoS One Date: 2015-02-09 Impact factor: 3.240